Alfred Garfall, MD, offers an update on advances in therapy for newly diagnosed multiple myeloma as reported at ASH 2017, beginning with the intensity of complex upfront therapy and maintenance following autologous stem cell transplantation (ASCT) with high-dose melphalan. The study of interest in induction therapy remains SWOG S0777 (as it was in 2016), which found both progression-free survival and overall survival benefits for patients receiving lenalidomide, bortezomib and dexamethasone (RVD) induction. Dr. Garfall also considers ongoing studies at Penn and considers high-dose melphalan+ASCT and the management of bone disease in MM.
Enrolling Clinical Trials: Umbilical Cord Blood Transplantation vs Haploidentical Transplantation for Patients with Hematological Malignancies
Connect on Doximity
Dr Garfall’s Profile